Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Bifikafusp alfa + onfekafusp alfa by Philogen for Kaposi Sarcoma: Likelihood of Approval
Bifikafusp alfa + onfekafusp alfa is under clinical development by Philogen and currently in Phase II for Kaposi Sarcoma. According...
Bifikafusp alfa + onfekafusp alfa by Philogen for Metastatic Melanoma: Likelihood of Approval
Bifikafusp alfa + onfekafusp alfa is under clinical development by Philogen and currently in Phase III for Metastatic Melanoma. According...
Bifikafusp alfa + onfekafusp alfa by Philogen for Keratoacanthoma: Likelihood of Approval
Bifikafusp alfa + onfekafusp alfa is under clinical development by Philogen and currently in Phase II for Keratoacanthoma. According to...
Bifikafusp alfa + onfekafusp alfa by Philogen for Cutaneous T-Cell Lymphoma: Likelihood of Approval
Bifikafusp alfa + onfekafusp alfa is under clinical development by Philogen and currently in Phase II for Cutaneous T-Cell Lymphoma....
Bifikafusp alfa + onfekafusp alfa by Philogen for Merkel Cell Carcinoma: Likelihood of Approval
Bifikafusp alfa + onfekafusp alfa is under clinical development by Philogen and currently in Phase II for Merkel Cell Carcinoma....
Bifikafusp alfa + onfekafusp alfa by Philogen for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
Bifikafusp alfa + onfekafusp alfa is under clinical development by Philogen and currently in Phase II for Cutaneous Squamous Cell...
Bifikafusp alfa + onfekafusp alfa by Philogen for Basal Cell Carcinoma (Basal Cell Epithelioma): Likelihood of Approval
Bifikafusp alfa + onfekafusp alfa is under clinical development by Philogen and currently in Phase II for Basal Cell Carcinoma...